JP2012501986A5 - - Google Patents

Download PDF

Info

Publication number
JP2012501986A5
JP2012501986A5 JP2011525465A JP2011525465A JP2012501986A5 JP 2012501986 A5 JP2012501986 A5 JP 2012501986A5 JP 2011525465 A JP2011525465 A JP 2011525465A JP 2011525465 A JP2011525465 A JP 2011525465A JP 2012501986 A5 JP2012501986 A5 JP 2012501986A5
Authority
JP
Japan
Prior art keywords
pain
medicament
preparation
treatment
combination according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011525465A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012501986A (ja
JP5731387B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2009/006424 external-priority patent/WO2010025931A2/en
Publication of JP2012501986A publication Critical patent/JP2012501986A/ja
Publication of JP2012501986A5 publication Critical patent/JP2012501986A5/ja
Application granted granted Critical
Publication of JP5731387B2 publication Critical patent/JP5731387B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011525465A 2008-09-05 2009-09-04 医薬配合剤 Active JP5731387B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08015625 2008-09-05
EP08015625.0 2008-09-05
PCT/EP2009/006424 WO2010025931A2 (en) 2008-09-05 2009-09-04 Pharmaceutical combination

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014251851A Division JP2015096530A (ja) 2008-09-05 2014-12-12 医薬配合剤

Publications (3)

Publication Number Publication Date
JP2012501986A JP2012501986A (ja) 2012-01-26
JP2012501986A5 true JP2012501986A5 (OSRAM) 2014-07-24
JP5731387B2 JP5731387B2 (ja) 2015-06-10

Family

ID=40345058

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2011525465A Active JP5731387B2 (ja) 2008-09-05 2009-09-04 医薬配合剤
JP2014251851A Pending JP2015096530A (ja) 2008-09-05 2014-12-12 医薬配合剤
JP2016240032A Pending JP2017071636A (ja) 2008-09-05 2016-12-12 医薬配合剤
JP2019070282A Pending JP2019131578A (ja) 2008-09-05 2019-04-02 医薬配合剤

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2014251851A Pending JP2015096530A (ja) 2008-09-05 2014-12-12 医薬配合剤
JP2016240032A Pending JP2017071636A (ja) 2008-09-05 2016-12-12 医薬配合剤
JP2019070282A Pending JP2019131578A (ja) 2008-09-05 2019-04-02 医薬配合剤

Country Status (28)

Country Link
US (1) US20100063148A1 (OSRAM)
EP (2) EP2735338B1 (OSRAM)
JP (4) JP5731387B2 (OSRAM)
KR (3) KR101730924B1 (OSRAM)
CN (2) CN105520924B (OSRAM)
AR (2) AR073361A1 (OSRAM)
AU (3) AU2009289776A1 (OSRAM)
BR (1) BRPI0920521A2 (OSRAM)
CA (1) CA2735857C (OSRAM)
CL (1) CL2011000317A1 (OSRAM)
CO (1) CO6382142A2 (OSRAM)
CY (2) CY1115751T1 (OSRAM)
DK (2) DK2735338T3 (OSRAM)
EC (1) ECSP11010869A (OSRAM)
ES (2) ES2513394T3 (OSRAM)
HR (2) HRP20140663T1 (OSRAM)
HU (1) HUE043278T2 (OSRAM)
IL (3) IL211135A (OSRAM)
LT (1) LT2735338T (OSRAM)
MX (1) MX2011002339A (OSRAM)
PE (5) PE20142371A1 (OSRAM)
PL (2) PL2331210T3 (OSRAM)
PT (2) PT2735338T (OSRAM)
RU (2) RU2571501C2 (OSRAM)
SI (2) SI2735338T1 (OSRAM)
TR (1) TR201904388T4 (OSRAM)
WO (1) WO2010025931A2 (OSRAM)
ZA (1) ZA201101449B (OSRAM)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US20060159743A1 (en) * 2001-10-25 2006-07-20 Depomed, Inc. Methods of treating non-nociceptive pain states with gastric retentive gabapentin
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
US20090176882A1 (en) 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
CN102846601B (zh) 2006-06-15 2015-04-29 优时比制药有限公司 具有协同抗惊厥作用的药物组合物
US20100190752A1 (en) 2008-09-05 2010-07-29 Gruenenthal Gmbh Pharmaceutical Combination
WO2010025931A2 (en) * 2008-09-05 2010-03-11 Grünenthal GmbH Pharmaceutical combination
FR2943246B1 (fr) * 2009-03-19 2011-07-29 Biocodex Compose pour son utilisation dans le traitement des neuropathies peripheriques
KR101831616B1 (ko) * 2010-06-15 2018-04-04 그뤼넨탈 게엠베하 통증 치료용 약제학적 병용물
BR112013000190A2 (pt) 2010-07-06 2017-11-07 Gruenenthal Gmbh formas de dosagem de retenção gástrica compreendendo um análogo de gaba e um opioide
WO2012015027A1 (ja) 2010-07-30 2012-02-02 東レ株式会社 神経障害性疼痛の治療剤又は予防剤
KR101970468B1 (ko) * 2011-03-04 2019-04-19 그뤼넨탈 게엠베하 타펜타돌의 비경구 투여
US11413239B2 (en) * 2011-07-20 2022-08-16 Torrent Pharmaceuticals Ltd. Pharmaceutical composition of tapentadol for nasal administration
PL2736501T3 (pl) * 2011-07-29 2018-06-29 Grünenthal GmbH Dooponowe lub nadtwardówkowe podawanie 3-[(1S,2S)-3-(dimetyloamino)-1-etylo-2-metylopropylo]fenolu
US20130310385A1 (en) 2012-05-18 2013-11-21 Gruenenthal Gmbh Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine and Antidepressants
US9320725B2 (en) 2012-05-18 2016-04-26 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a gabapentinoid
US9345689B2 (en) * 2012-05-18 2016-05-24 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N, N-dimethyl-4-phenyl-4,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and an anticonvulsant
US9320729B2 (en) 2012-05-18 2016-04-26 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-flouro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a propionic acid derivative
US9855286B2 (en) 2012-05-18 2018-01-02 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-di methyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a salicylic acid component
US20130310435A1 (en) * 2012-05-18 2013-11-21 Gruenenthal Gmbh Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N, N-dimethyl-4-phenyl-4,9' -dihydro-3'H-spiro[cyclohexane-1,1' -pyrano[3,4,b]indol]-4-amine and Paracetamol or Propacetamol
US8912226B2 (en) * 2012-05-18 2014-12-16 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r) -6′-fluoro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a NSAR
US9308196B2 (en) * 2012-05-18 2016-04-12 Gruenenthal Gmbh Pharmaceutical composition comprising (1 r,4r) -6'-fluoro-N ,N-dimethyl-4-phenyl-4',9'-d ihydro-3'H-spiro[cyclohexane-1,1'-pyrano-[3,4,b]indol]-4-amine and an oxicam
US9629818B2 (en) * 2012-11-01 2017-04-25 Torrent Pharmaceuticals Ltd. Pharmaceutical composition of tapentadol for parenteral administration
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US9549909B2 (en) 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
CN103655523A (zh) * 2013-12-24 2014-03-26 南京艾德凯腾生物医药有限责任公司 他喷他多组合物
KR20180095674A (ko) 2015-12-22 2018-08-27 조게닉스 인터내셔널 리미티드 대사 저항성 펜플루라민 유사체 및 그 사용 방법
SG11201804811WA (en) 2015-12-22 2018-07-30 Zogenix International Ltd Fenfluramine compositions and methods of preparing the same
RU2746000C2 (ru) 2016-08-24 2021-04-05 Зодженикс Интернэшнл Лимитед Состав для ингибирования образования агонистов 5-ht2b и способы его применения
US10682317B2 (en) 2017-09-26 2020-06-16 Zogenix International Limited Ketogenic diet compatible fenfluramine formulation
KR20190081385A (ko) 2017-12-29 2019-07-09 강원대학교산학협력단 옥스카바제핀을 유효성분으로 함유하는 허혈성 뇌혈관 질환 예방용 조성물
JP2021526507A (ja) 2018-05-11 2021-10-07 ゾゲニクス インターナショナル リミテッド 発作により誘発される突然死を処置するための組成物および方法
US12144787B2 (en) 2018-11-19 2024-11-19 Zogenix International Limited Method of treating patients with a mutation in cyclin-dependent kinase-like 5 (CDKL5)
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4389393A (en) 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4765989A (en) 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US4612008A (en) 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US4783337A (en) 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US5472711A (en) 1992-07-30 1995-12-05 Edward Mendell Co., Inc. Agglomerated hydrophilic complexes with multi-phasic release characteristics
US5330761A (en) 1993-01-29 1994-07-19 Edward Mendell Co. Inc. Bioadhesive tablet for non-systemic use products
US5455046A (en) 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5399362A (en) 1994-04-25 1995-03-21 Edward Mendell Co., Inc. Once-a-day metoprolol oral dosage form
DE4426245A1 (de) 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
EA006598B1 (ru) * 1999-08-20 2006-02-24 Орто-Макнейл Фармасьютикал, Инк. Композиция, содержащая трамадол и противосудорожное лекарственное средство
CA2473536A1 (en) * 2002-01-16 2003-07-31 Endo Pharmaceuticals, Inc. Pharmaceutical composition and method for treating disorders of the central nervous system
WO2003070237A1 (en) * 2002-02-22 2003-08-28 Warner-Lambert Company Llc Combinations of an alpha-2-delta ligand with a selective inhibitor of cyclooxygenase-2
WO2007005716A2 (en) * 2005-06-30 2007-01-11 Cinergen, Llc Methods of treatment and compositions for use thereof
US20090082466A1 (en) * 2006-01-27 2009-03-26 Najib Babul Abuse Resistant and Extended Release Formulations and Method of Use Thereof
CN102671195B (zh) * 2006-04-28 2016-01-20 格吕伦塔尔有限公司 包含3-(3-二甲基氨基-1-乙基-2-甲基-丙基)-苯酚和nsaid的药物组合物
WO2008027442A2 (en) * 2006-08-30 2008-03-06 Theraquest Biosciences, Llc Abuse deterrent oral pharmaceutical formulations of opioid agonists and method of use
PL2596784T3 (pl) * 2007-11-23 2017-06-30 Grünenthal GmbH Kompozycje tapentadolu
TWI380812B (zh) * 2008-01-25 2013-01-01 Xenoport Inc (3s)-胺甲基-5-甲基己酸前藥之晶形及使用方法
WO2010025931A2 (en) * 2008-09-05 2010-03-11 Grünenthal GmbH Pharmaceutical combination

Similar Documents

Publication Publication Date Title
JP2012501986A5 (OSRAM)
MX2010003299A (es) Oligonucleotidos muy cortos (micromirs).
CY1118813T1 (el) Φαρμακευτικες συνθεσεις συν-κρυσταλλων τραμαδολης και κοξιμπων
WO2012088266A3 (en) Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
JP2014530840A5 (OSRAM)
SMT201600273B (it) Genz 112638 per trattare la malattia di gaucher o fabry in terapia di combinazione
IL216599A (en) 4,1-Bi-Conjugated Phthalazine History, Pharmaceuticals Containing Them and Their Use in Cancer Treatment
MX344238B (es) Compuestos de tetrazol y métodos para preparar y usar los mismos.
JP2013514381A5 (OSRAM)
BRPI1012116A2 (pt) composição farmacêutica para o tratamento de doenças cardíacas
CY1114960T1 (el) Συνθεσεις που περιλαμβανουν τραμαδολη και σελεκοξιμπη στην θεραπεια πονου
JP2015504870A5 (OSRAM)
JP2011528248A5 (OSRAM)
JP2013231052A5 (OSRAM)
JP2012516348A5 (OSRAM)
JP2014054318A5 (OSRAM)
JP2009532412A5 (OSRAM)
WO2015004634A3 (es) Combinación sinergística de paracetamol/celecoxib para el tratamiento de dolor inflamatorio
JP2009126813A5 (OSRAM)
TH92434B (th) เก้าอี้
UA102529C2 (en) Microribonucleic acids
TH102233B (th) เตียงนอนแบบปรับระดับพนักพิง
JP2007151536A5 (OSRAM)
TH93116B (th) เก้าอี้
TH98964B (th) เก้าอี้